- Home
- MDIA vs OPTN Comparison
MDIA vs OPTN Comparison
Compare MDIA & OPTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDIA
- OPTN
- Stock Information
- Founded
- MDIA 2019
- OPTN 2010
- Country
- MDIA United States
- OPTN United States
- Employees
- MDIA N/A
- OPTN N/A
- Industry
- MDIA Broadcasting
- OPTN Biotechnology: Pharmaceutical Preparations
- Sector
- MDIA Consumer Discretionary
- OPTN Health Care
- Exchange
- MDIA Nasdaq
- OPTN Nasdaq
- Market Cap
- MDIA 55.6M
- OPTN 55.4M
- IPO Year
- MDIA N/A
- OPTN 2017
- Fundamental
- Price
- MDIA $1.09
- OPTN $5.45
- Analyst Decision
- MDIA
- OPTN Strong Buy
- Analyst Count
- MDIA 0
- OPTN 3
- Target Price
- MDIA N/A
- OPTN $16.67
- AVG Volume (30 Days)
- MDIA 16.4K
- OPTN 18.0K
- Earning Date
- MDIA 03-31-2025
- OPTN 03-18-2025
- Dividend Yield
- MDIA N/A
- OPTN N/A
- EPS Growth
- MDIA N/A
- OPTN N/A
- EPS
- MDIA N/A
- OPTN N/A
- Revenue
- MDIA $69,296,000.00
- OPTN $75,672,000.00
- Revenue This Year
- MDIA N/A
- OPTN $13.42
- Revenue Next Year
- MDIA N/A
- OPTN $38.54
- P/E Ratio
- MDIA N/A
- OPTN N/A
- Revenue Growth
- MDIA 94.96
- OPTN 5.13
- 52 Week Low
- MDIA $0.40
- OPTN $4.82
- 52 Week High
- MDIA $6.86
- OPTN $31.50
- Technical
- Relative Strength Index (RSI)
- MDIA 44.65
- OPTN 44.79
- Support Level
- MDIA $1.00
- OPTN $5.11
- Resistance Level
- MDIA $1.23
- OPTN $5.61
- Average True Range (ATR)
- MDIA 0.08
- OPTN 0.46
- MACD
- MDIA -0.00
- OPTN -0.00
- Stochastic Oscillator
- MDIA 38.46
- OPTN 25.18
About MDIA Mediaco Holding Inc.
MediaCo Holding Inc is a radio broadcasting media company operating in radio and digital advertising, premium programming and events. It has two radio stations, WQHT-FM and WBLS-FM, which serve the New York City metropolitan area. The company generates revenue from radio and outdoor advertising sales and events including sponsorships and ticket sales, licensing, and syndication.
About OPTN OptiNose Inc.
OptiNose Inc is a specialty pharmaceutical company focuses on the development and commercialization of products for patients treated by ear, nose, and throat (ENT), and allergy specialists. Its first commercial product, XHANCE (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing the proprietary Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.